Ингибирование теломеразы человека (1105569), страница 16
Текст из файла (страница 16)
V. 28. P. 1945-1952.Harley C.B. Telomerase and cancer therapeutics. // Nat Rev Cancer. 2008. V.8. P. 167-179.Brunsvig P.F., Kyte J.A., Kersten C., Sundstrom S., Moller M., Nyakas M.,Hansen G.L., Gaudernack G., Aamdal S. Telomerase peptide vaccination inNSCLC: a phase II trial in stage III patients vaccinated afterchemoradiotherapy and an 8-year update on a phase I/II trial. // Clin CancerRes.
2011. V. 17. P. 6847-6857.Williams S.C. No end in sight for telomerase-targeted cancer drugs. // NatMed. 2013. V. 19. P. 6.Middleton G., Silcocks P., Cox T., Valle J., Wadsley J., Propper D., CoxonF., Ross P., Madhusudan S., Roques T., Cunningham D., Falk S., Wadd N.,Harrison M., Corrie P., Iveson T., Robinson A., McAdam K., Eatock M.,Evans J., Archer C., Hickish T., Garcia-Alonso A., Nicolson M., Steward W.,Anthoney A., Greenhalf W., Shaw V., Costello E., Naisbitt D., Rawcliffe C.,Nanson G., Neoptolemos J.
Gemcitabine and capecitabine with or withouttelomerase peptide vaccine GV1001 in patients with locally advanced ormetastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3trial. // Lancet Oncol. 2014. V. 15. P. 829-840.Huo L.F., Tang J.W., Huang J.J., Huang P.T., Huang C.F., Kung H.F., LinM.C. Cancer immunotherapy targeting the telomerase reverse transcriptase. //Cell Mol Immunol. 2006. V.
3. P. 1–11.DiPersio J.F., Collins Jr R.H., Blum W., Devetten M.P., Stiff P., Elias L., etal. Immune responses in AML patients following vaccination withGRNVAC1, autologous RNA transfected dendritic cells expressingtelomerase catalytic subunit hTERT. // ASH Annu Meeting Abstr. 2009.
V.120[25][26][27][28][29][30][31][32][33][34][35]114. P. 633.Su Z., Dannull J., Yang B.K., Dahm P., Coleman D., Yancey D., Sichi S.,Niedzwiecki D., Boczkowski D., Gilboa E., Vieweg J. Telomerase mRNAtransfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cellresponses in patients with metastatic prostate cancer. // J Immunol.
2005. V.174. P. 3798-3807.Su Z., Vieweg J., Weizer A.Z., Dahm P., Yancey D., Turaga V., et al.Enhanced induction of telomerase-specific CD4(+) T cells using dendriticcells transfected with RNA encoding a chimeric gene product. // Cancer Res.2002. V. 62. P. 5041–5048.URL: http://ir.geron.com/phoenix.zhtml?c=67323&p=irolnewsArticle&ID=1636173.Kobayashi A., Weinberg V., Darragh T., Smith-McCune K. Evolvingimmunosuppressive microenvironment during human cervical carcinogenesis.// Mucosal Immunol. 2008. V.
1. P. 412-420.Jacob D., Davis J., Zhu H., Zhang L., Teraishi F., Wu S., Marini F.C., FangB. Suppressing orthotopic pancreatic tumor growth with a fiber-modifiedadenovector expressing the TRAIL gene from the human telomerase reversetranscriptase promoter. // Clin Cancer Res. 2004. V. 10. P. 3535-3541.Li Y., Idamakanti N., Arroyo T., Thorne S., Reid T., Nichols S., VanRoey M.,Colbern G., Nguyen N., Tam O., Working P., Yu D.C. Dual promotercontrolled oncolytic adenovirus CG5757 has strong tumor selectivity andsignificant antitumor efficacy in preclinical models.
// Clin Cancer Res. 2005.V. 11. P. 8845-8855.Nemunaitis J., Tong A.W., Nemunaitis M., Senzer N., Phadke A.P., BedellC., Adams N., Zhang Y.A., Maples P.B., Chen S., Pappen B., Burke J.,Ichimaru D., Urata Y., Fujiwara T. A Phase I Study of Telomerase-specificReplication Competent Oncolytic Adenovirus (Telomelysin) for VariousSolid Tumors. // Mol Ther.
2009. V. 18. P. 429-34.Brower V. Telomerase-Based Therapies Emerging Slowly. // J Natl CancerInst. 2010. V. 102. P. 520-521.Boukamp P., Popp S., Krunic D. Telomere-dependent chromosomalinstability. // J Investig Dermatol Symp Proc. 2005. V. 10. P. 89-94.Phatak P., Burger A.M. Telomerase and its potential for therapeuticintervention.
// Br J Pharmacol. 2007. V. 152. P. 1003-1011.Cao Y., Huschtscha L.I., Nouwens A.S., Pickett H.A., Neumann A.A., ChangA.C., Toouli C.D., Bryan T.M., Reddel R.R. Amplification of telomerasereverse transcriptase gene in human mammary epithelial cells with limiting121[36][37][38][39][40][41][42][43][44][45][46]telomerase RNA expression levels. // Cancer Res. 2008. V. 68.
P. 3115–3123.Morin G. The Human Telomere Terminal Transferase Enzyme Is aRibonucleoprotein That Synthesizes TTAGGG Repeats. // Cell. 1989. V. 59.P. 521-529.Fajkus J. Detection of telomerase activity by the TRAP assay and its variantsand alternatives. // Clinica Chimica Acta. 2006. V. 371. P. 25–31.Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.,Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific associationof human telomerase activity with immortal cells and cancer.
// Science. 1994.V. 266. P. 2011-2015.Kim N.W., Wu F. Advances in quantification and characterization oftelomerase activity by the telomeric repeat amplification protocol (TRAP). //Nucleic Acids Res. 1997. V. 25. P. 2595-2597.De Cian A., Cristofari G., Reichenbach P., De Lemos E., Monchaud D.,Teulade-Fichou M.P., Shin-Ya K., Lacroix L., Lingner J., Mergny J.L.Reevaluation of telomerase inhibition by quadruplex ligands and theirmechanisms of action.
// Proc Natl Acad Sci U S A. 2007. V. 104. P. 1734717352.Piotrowska K., Kleideiter E., Mürdter T.E., Taetz S., Baldes C., Schaefer U.,Lehr C.M., Klotz U. Optimization of the TRAP assay to evaluate specificityof telomerase inhibitors. // Lab Invest. 2005. P. 85. V. 1565-1569.Pascolo E., Wenz C., Lingner J., Hauel N., Priepke H., Kauffmann I., GarinChesa P., Rettig W.J., Damm K., Schnapp A. Mechanism of humantelomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drugcandidate. // J Biol Chem.
2002. V. 277. P. 15566-15572.Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., PriepkeH., Niestroj C., Daiber C., Enenkel B., Guilliard B., Lauritsch I., Müller E.,Pascolo E., Sauter G., Pantic M., Martens U.M., Wenz C., Lingner J., KrautN., Rettig W.J., Schnapp A. A highly selective telomerase inhibitor limitinghuman cancer cell proliferation. // EMBO. 2002. V. 20. P.
6958–6968.Wu K.L., Wilkinson S., Reich N.O., Pettus T.R. Facile synthesis ofnaphthoquinone spiroketals by diastereoselective oxidative [3 + 2]cycloaddition. // Org Lett. 2007. V. 9. P. 5537-5540.Barma D.K., Elayadi A., Falck J.R., Corey D.R. Inhibition of telomerase byBIBR 1532 and related analogues. // Bioorg Med Chem Lett. 2003. V. 13. P.1333-1336.Cohn E.P., Wu K.L., Pettus T.R., Reich N.O. A new strategy for detectionand development of tractable telomerase inhibitors. // J Med Chem.
2002. V.122[47][48][49][50][51][52][53][54][55][56][57][58]55. P. 3678-3686.Wege H., Chui M.S., Le H.T., Tran J.M., Zern M.A. SYBR Green real-timetelomeric repeat amplification protocol for the rapid quantification oftelomerase activity. // Nucleic Acids Res. 2003. V. 31. P. E3-3.Uehara H., Nardone G., Nazarenko I., Hohman R.J. Detection of telomeraseactivity utilizing energy transfer primers: comparison with gel- and ELISAbased detection. // Biotechniques.
1999. V. 26. P. 552-558.Rossetti L., Franceschin M., Bianco A., Ortaggi G., Savino M. Perylenediimides with different side chains are selective in inducing different Gquadruplex DNA structures and in inhibiting telomerase. // Bioorg Med ChemLett. 2002. V. 12. P. 2527-2533.Oda M., Ueno T., Kasai N., Takahashi H., Yoshida H., Sugawara F.,Sakaguchi K., Hayashi H., Mizushina Y. Inhibition of telomerase by linearchain fatty acids: a structural analysis. // Biochem J. 2002. V. 367. P. 329-334.Reed J., Gunaratnam M., Beltran M., Reszka A.P., Vilar R., Neidle S.
TRAPLIG, a modified telomere repeat amplification protocol assay to quantitatetelomerase inhibition by small molecules. // Anal Biochem. 2008. V. 380. P.99-105.Gollahon L.S., Holt S.E. Alternative methods of extracting telomerase activityfrom human tumor samples. // Cancer Lett. 2000. V. 159. P. 141-149.Zendehrokh N., Dejmek A. Telomere repeat amplification protocol (TRAP) insitu reveals telomerase activity in three cell types in effusions: malignantcells, proliferative mesothelial cells, and lymphocytes. // Mod Pathol. 2005.V. 18. P.
189-196.Herbert B., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W.,Corey D.R. Inhibition of human telomerase in immortal human cells leads toprogressive telomere shortening and cell death. // Proc Natl Acad Sci U S A.2012. V. 96. P. 14276-14281.Wishart D.S. Small molecules and disease. // PLoS Comput Biol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
